It makes sense and dollars to buy Amicus Therapeutics Inc. (FOLD) stock

Amicus Therapeutics Inc. (NASDAQ: FOLD) stock jumped 2.53% on Tuesday to $13.39 against a previous-day closing price of $13.06. With 1.49 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.3 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $13.44 whereas the lowest price it dropped to was $12.80. The 52-week range on FOLD shows that it touched its highest point at $13.61 and its lowest point at $5.91 during that stretch. It currently has a 1-year price target of $15.40. Beta for the stock currently stands at 0.86.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of FOLD was up-trending over the past week, with a rise of 7.81%, but this was up by 11.86% over a month. Three-month performance surged to 20.52% while six-month performance rose 30.00%. The stock gained 48.94% in the past year, while it has gained 9.66% so far this year. A look at the trailing 12-month EPS for FOLD yields -0.91 with Next year EPS estimates of -0.29. For the next quarter, that number is -0.12. This implies an EPS growth rate of 13.70% for this year and 61.30% for next year.

Float and Shares Shorts:

At present, 289.22 million FOLD shares are outstanding with a float of 251.96 million shares on hand for trading. On Oct 13, 2022, short shares totaled 20.78 million, which was 7.41% higher than short shares on Sep 14, 2022. In addition to Mr. John F. Crowley as the firm’s Exec. Chairman, Mr. Bradley L. Campbell M.B.A. serves as its CEO, Pres & Director.


Institutional Ownership:

Through their ownership of 111.95% of FOLD’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 60.61% of FOLD, in contrast to 41.94% held by mutual funds. Shares owned by individuals account for 24.02%. As the largest shareholder in FOLD with 9.74% of the stake, Perceptive Advisors LLC holds 27,372,917 shares worth 27,372,917. A second-largest stockholder of FOLD, Avoro Capital Advisor LLC, holds 26,800,000 shares, controlling over 9.54% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in FOLD, holding 25,184,643 shares or 8.96% stake. With a 3.03% stake in FOLD, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 8,522,463 shares are owned by the mutual fund manager. The Vanguard Small Cap Index Fund, which owns about 2.58% of FOLD stock, is the second-largest Mutual Fund holder. It holds 7,238,730 shares valued at 88.38 million. SPDR S&P Biotech ETF holds 2.41% of the stake in FOLD, owning 6,771,015 shares worth 82.67 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for FOLD since 13 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With FOLD analysts setting a high price target of $20.00 and a low target of $10.00, the average target price over the next 12 months is $15.00. Based on these targets, FOLD could surge 49.37% to reach the target high and fall by -25.32% to reach the target low. Reaching the average price target will result in a growth of 12.02% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. FOLD will report FY 2022 earnings on 02/22/2024. Analysts have provided yearly estimates in a range of -$0.64 being high and -$0.86 being low. For FOLD, this leads to a yearly average estimate of -$0.77. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Amicus Therapeutics Inc. surprised analysts by $0.07 when it reported -$0.12 EPS against a consensus estimate of -$0.19. The surprise factor in the prior quarter was $0.00. Based on analyst estimates, the high estimate for the next quarter is $0.03 and the low estimate is -$0.24. The average estimate for the next quarter is thus -$0.11.

Summary of Insider Activity:

Insiders traded FOLD stock several times over the past three months with 9 Buys and 28 Sells. In these transactions, 706,848 shares were bought while 386,529 shares were sold. The number of buy transactions has increased to 25 while that of sell transactions has risen to 57 over the past year. The total number of shares bought during that period was 981,707 while 671,797 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *